Health and Human Services Secretary Robert F. Kennedy Jr. has canceled $500 million in mRNA vaccine research funding, a move that public health experts warn could leave the U.S. vulnerable to future pandemics and hinder medical innovation.
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr.’s recent decision to terminate $500 million in funding for mRNA vaccine research has raised significant concerns among public health experts and stakeholders. They argue that this move may leave the United States ill-prepared for the next pandemic and undermine ongoing advancements in medical treatments.
Former Surgeon General Jerome Adams expressed his worries in a post on social media platform X, stating: “I’ve tried to be objective & non-alarmist in response to current HHS actions—but quite frankly this move is going to cost lives.” Adams highlighted that mRNA technology’s applications extend beyond vaccines and credited the rapid development of COVID-19 vaccines with saving millions of lives.
In 2021, Pfizer and Moderna introduced the first COVID-19 mRNA vaccines, marking a pivotal moment as these vaccines were developed in record time, supported by Operation Warp Speed initiated under the Trump administration. The effectiveness and safety of these vaccines were pivotal in bringing the pandemic under control, and experts believe mRNA technology holds transformative potential for combating emerging diseases, including bird flu, due to its modifiable nature.
Kennedy’s decision targets contracts funded by the Biomedical Advanced Research and Development Authority (BARDA) and shifts focus to platforms considered to have “stronger safety records.” This shift has drawn criticism from the scientific community, which argues that extensive data from the distribution of millions of mRNA doses worldwide indicates a minimal occurrence of adverse events.
Jeff Coller, a professor at Johns Hopkins University, criticized the move as politically motivated against mRNA technology. He warns that it may set back U.S. biomedical research, sending a discouraging signal to scientists and investors alike about the viability of mRNA technology in the U.S., particularly in securing federal support.
Jennifer Nuzzo, a professor of epidemiology and director of the Pandemic Center at Brown University, highlighted national security implications. She warned that the United States’ apparent withdrawal from preparedness efforts might embolden adversaries to exploit weaknesses in public health defenses, including through biological warfare. “One of the ways that we deter that from happening is to say the United States is absolutely committed to preparedness,” she emphasized.
Furthermore, Nuzzo pointed out that reducing research into mRNA vaccine platforms could stifle innovation in medical treatments emerging from the U.S., including potential cancer solutions. “It’s troubling on a number of fronts,” she cautioned, noting preliminary studies suggesting mRNA technology’s promise in treating cancer by targeting specific genetic signatures.
Although the canceled contracts do not directly impact cancer research, Michael Osterholm, founding director of the Center for Infectious Disease Research and Policy, remarked on the chilling effect the move may have on researchers. He fears it could deter investments in mRNA technology, potentially hindering the development of vaccines for various infectious diseases.
Kennedy’s skepticism toward vaccines, particularly mRNA-based ones, has been evident since he falsely labeled COVID-19 vaccines as exceptionally dangerous. The decision also follows criticism over the FDA’s approval of an updated Moderna COVID-19 vaccine, even with limited use in children.
In a recent video, Kennedy again made unsubstantiated claims about mRNA vaccines, arguing they don’t protect against respiratory viruses and are ineffective if a virus mutates. This continues to fuel debate among health experts who are urging Congress to reinstate funding for mRNA research, describing Kennedy’s actions as an attack on sound federal vaccine policy.
Demanding action, Robert Steinbrook of the Public Citizen Health Research Group stated, “The HHS Secretary continues a mindless assault on sound federal vaccine policy.” He underscored the mRNA platform’s critical role in the rapid development and distribution of vaccines during the COVID-19 pandemic and its ongoing importance in future health emergency preparedness.
The full consequences of Kennedy’s funding cut remain unclear. A spokesperson from Moderna mentioned they were unaware of any recent cancellations beyond a previously terminated H5N1 bird flu vaccine contract. Additionally, Gritstone bio, which was also on the list of canceled contracts, had ceased operations after filing for bankruptcy. Meanwhile, Tiba Biotech, whose contract was for a therapeutic using RNA interference rather than mRNA technology, expressed surprise over the contract termination.